Russia Approves Sputnik-V Vaccine Despite Incomplete Testing
Russia grants emergency approval to a covid-19 vaccine named Sputnik-V, though it lacks completed large-scale clinical trials. The fast-tracked move serves as a point of national pride and could intensify the global vaccine race.
Russia grants emergency approval to a covid-19 vaccine called Sputnik-V, with President Vladimir Putin claiming it successfully passes all necessary tests. The vaccine originates from the Gamaleya National Research Center in Moscow and utilizes an adenovirus to deliver coronavirus components, mirroring the approach of the Oxford and AstraZeneca candidate. Putin even states that one of his daughters receives the inoculation as part of the experiment.
Despite the official clearance, Russia does not finish the large-scale human studies required to prove the shot is safe and effective against the virus. Health-care workers, doctors, and teachers receive the first doses when supplies become available in October, with a broader public rollout planned for January. The country currently reports nearly 900,000 covid-19 infections, the fourth-highest total globally.
The name Sputnik-V deliberately references the 1957 Soviet space satellite, framing the vaccine as a triumph of Russian scientific prowess and a tool of geopolitical influence. This bold announcement puts pressure on the United States and the Operation Warp Speed program to accelerate their own emergency approvals, raising fears among scientists that unproven vaccines become pawns in political races. Meanwhile, China also moves forward with its own military-approved vaccine.